参考文献/References:
[1]鞠海兵.新诊断2型糖尿病患者短期胰岛素强化治疗后的药物选择[J].药品评价,2015,12(19):26-28,32. [2]中华医学会内分泌学分会.中国成人2型糖尿病口服降糖药联合治疗专家共识[J].中华内分泌代谢杂志,2019,35(3):190-199. [3]罗艳,胡桂英.二甲双胍联合艾塞那肽治疗2型糖尿病合并肥胖病患者的临床疗效[J].医学综述,2016,22(17):3484-3487. [4]王瑜,方煜,胡明.阿格列汀治疗2型糖尿病的药物经济学评价[J].中国药房,2016,27(26):3605-3609. [5]马淑芳.胰高血糖素样肽1类药物在2型糖尿病治疗中的应用[J].医学综述,2014,20(16):2978-2980. [6]杨松,谷媛媛,李兆亮,等.沙格列汀或格列美脲联合甘精胰岛素对2型糖尿病患者血糖波动影响的观察[J].中国糖尿病杂志,2015,23(3):237-240. [7]郭西华,张小红.仙鹤草降糖散治疗2型糖尿病的临床效果对照研究[J].中国当代医药,2015,29(13):157-160. [8]王晓茜,肖斌,王森,等.西格列汀治疗2型糖尿病31例疗效观察[J].陕西医学杂志,2016,45(7):897-899. [9]姚璐,田国祥,武云涛,等.二甲双胍分别联合利拉鲁肽及甘精胰岛素治疗2型糖尿病的临床观察[J].中国循证心血管医学杂志,2015,7(1):100-102. [10]白银涛,潭子新,王琰,等.血管内皮细胞钙黏蛋白在2型糖尿病患者中的表达及临床意义[J].陕西医学杂志,2016,45(7):809-810. [11]哈斯,孟帮柱,巴图德力根,等.格列美脲片联合吡格列酮治疗2型糖尿病患者的临床研究[J].中国临床药理学杂志,2016,32(7):594-596. [12]黄云鸿,顾丽萍,丁晓颖,等.胰岛素联合二肽基肽酶4抑制剂治疗2型糖尿病的疗效观察[J].世界临床药物,2016,37(6):375-379. [13]何军儒,丁菊香,刘倩芳,等.瑞格列奈联合甘精胰岛素治疗2型糖尿病的疗效及对胰岛B细胞功能的影响[J].中国老年学杂志,2016,36(15):3720-3722. [14]王勇,王存川,朱晒红,等.中国肥胖及2型糖尿病外科治疗指南(2019版)[J].中国实用外科杂志,2019,4(39):304-305. [15]李有佳,李骏,唐景华.西格列汀与瑞格列奈治疗老年2型糖尿病的价值对照分析[J].海峡药学,2018,30(3):124-125. [16]刘雯.胰岛素联合利拉鲁肽治疗肥胖2型糖尿病的疗效及安全性[J].现代中西医结合杂志,2015,24(10):1085-1087. [17]安欣,孙媛媛.利拉鲁肽治疗肥胖2型糖尿病合并高脂血症的临床观察[J].陕西医学杂志,2015,44(8):1084-1085. [18]Scorsone A,Saura G,Fleres M,et al.Efficacy and renal safety of dapagliflozin in patients with type 2 diabetes mellitusalso receiving metformin:A real-life experience[J].J Diabetes Res,2018(2018):8501418. [19]叶启宝,何媛媛,吕齐欢,等.利拉鲁肽治疗2型糖尿病合并非酒精性脂肪肝患者的临床观察[J].医学研究杂志,2015,44(7):152-154. [20]蒋燕,孙良阁.阿卡波糖与二甲双胍配合甘精胰岛素治疗2型糖尿病效果对比[J].河南医学研究,2017,26(1):35-37. [21]杨震,董健,张军涛,等.达格列净在2型糖尿病合并心功能不全患者中应用的临床评价分析[J].重庆医学,2019,48(16):25-28. [22]韩秀平,孙涛,贺钰梅,等.磷酸西格列汀联合二甲双胍治疗初发2型糖尿病的临床效果[J].中国医药导报,2016,13(12):165-168. [23]Sattar N,McLaren J,Kristensen SL,et al.SGLT2 inhibition and ardiovascular events:why did EMPA—REG outcomes surpriseand what were the likely mechanisms[J].Diabetologia,2016,59(7):1333-1339. [24]王晶璞.甘精胰岛素联合二甲双胍改善2型糖尿病患者血糖控制水平的疗效[J].河北医药,2016,38(5):739-740. [25]安晓飞,赵越,余江毅,等.六味地黄丸联合银杏叶片防治2型糖尿病早期视网膜病变临床观察[J].中国中西医结合杂志,2016,36(6):674-677. [26]Hallow KM,Greasley PJ,Helmlinger G,et al.Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors:model-based analysis of clinical data[J].Am J Physiol Renal Physiol,2018,315(5):F1295-F1306. [27]Tomlinson B,Hu M,Zhang Y,et al. Effects of glu cose-lowering drugs on cardiovascular outcomes in patientswith type 2 diabetes[J].Expert Opin Drug Metab Toxicol,2016,12(11):1. [28]王荣,贾爱华,刘新艳,等.七味白术散合补阳还五汤治疗肥胖2型糖尿病及改善胰岛素抵抗的研究[J].实用医药杂志,2015,31(4):364-366.
相似文献/References:
[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in
Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(16):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,31(16):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的
相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,31(16):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(16):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,31(16):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2022,35(16):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Medical Information,2022,35(16):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[8]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Medical Information,2022,35(16):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[9]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Medical Information,2022,35(16):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[10]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行
健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,31(16):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]